Factor viia-polysialic acid conjugates having prolonged in vivo half-life

Abstract

The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.

1 . A proteinaceous construct comprising,
 (a) an activated factor VII (FVIIa) molecule selected from the group consisting of plasmatic FVIIa, recombinant FVIIa (rFVIIa), and a biologically active derivative of FVIIa; and   (b) at least one physiologically acceptable carbohydrate moiety comprising 1-4 sialic acid units bound to said FVIIa molecule;   wherein the in vivo half-life of said construct is prolonged in the blood of a mammal as compared to the in vivo half-life of a FVIIa molecule that is not bound to said carbohydrate moiety.   
     
     
         2 . The proteinaceous construct of  claim 1  wherein the in vivo half-life of said construct is increased by at least a factor of about two as compared to the in vivo half-life of a FVIIa molecule that is not bound to said carbohydrate moiety. 
     
     
         3 . The proteinaceous construct of  claim 1  wherein the in vivo half-life of said construct is increased by at least a factor of about three as compared to the in vivo half-life of a FVIIa molecule that is not bound to said carbohydrate moiety. 
     
     
         4 . The proteinaceous construct of  claim 1 , wherein the physiologically acceptable carbohydrate moiety is directly covalently linked to at least one amino acid residue of said FVIIa molecule. 
     
     
         5 . The proteinaceous construct of  claim 1 , wherein the physiologically acceptable carbohydrate moiety is non-covalently linked to at least one amino acid residue of said FVIIa molecule. 
     
     
         6 . The proteinaceous construct of  claim 1 , wherein said physiologically acceptable carbohydrate moiety is a polysialic acid or a derivative thereof. 
     
     
         7 . A pharmaceutical composition comprising an effective amount of the proteinaceous construct of  claim 1 , and one or more compounds selected from the group consisting of a pharmaceutically acceptable carrier, diluent, salt, buffer, and excipient. 
     
     
         8 . A method of controlling bleeding in a mammal having a bleeding disorder associated with functional defects or deficiencies of at least one of FVIIa, factor VIII (FVIII) and factor IX (FIX), said method comprising administering the proteinaceous construct of  claim 1 . 
     
     
         9 . A method of controlling bleeding in a mammal during surgery or trauma, said method comprising administering the proteinaceous construct of  claim 1 . 
     
     
         10 . A kit comprising a an effective amount of the proteinaceous construct of  claim 1 , packaged in a container, said kit optionally containing a second therapeutic agent, and further comprising a label attached to or packaged with the container, the label describing the contents of the container and providing indications and/or instructions regarding use of the contents of the container for controlling bleeding in a mammal. 
     
     
         11 . The kit of  claim 10  wherein the container is a vial or bottle or prefilled syringe.